HANSEN GWENN (Chief Scientific Officer) sold 1.2% of their position (1.45K shares) of NURIX THERAPEUTICS, INC. on the open market
Open‑market sale worth $37.0K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/1/2026ACC: 0001817160-26-000019
Officer· Chief Scientific Officer
Since Jul 2020
-1.45K
Net shares
Net seller
$37.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
1.45K acquired · 2.90K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+1.45K
Price / share
$1.86
Trade value
$2.70K
% of position
1.2%
9/1/2026
117.23K→118.68K
Common Stock
Direct
Shares
−1.45K
Price / share
$25.47
Trade value
$36.98K
% of position
1.2%
9/1/2026
118.68K→117.23K
Total
Net shares
+0.00
Net value
-$34.28K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/1/2026 | M · Option Exercise | +1.45K | $1.86 | $2.70K | 1.2% | 117.23K | 118.68K |
| Common Stock Direct | 9/1/2026 | S · Sale | −1.45K | $25.47 | $36.98K | 1.2% | 118.68K | 117.23K |
| Total | +0.00 | -$34.28K | ||||||
Derivative Transactions1
Employee Stock Option (right to buy)
Direct
Converts to
Common Stock
1.45K shares
Shares
−1.45K
Strike price
1.86
Held after
60.86K
Exercisable
—
9/1/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock1.45K shares | 9/1/2026 | M · Option Exercise | −1.45K | 1.86 | — | 60.86K |